The effect of flecainide acetate on fetal heart rate variability: A case report
Fetal supraventricular tachycardia is most often treated by maternal application of digoxin. A drug used for second-choice therapy is flecainide acetate. For a case in which maternal digoxin therapy failed, flecainide caused a lowering of the fetal heart rate (FHR) but, simultaneously, variability a...
Gespeichert in:
| Veröffentlicht in: | Obstetrics and gynecology (New York. 1953) 1995-10, Vol.86 (4), p.667-669 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 669 |
|---|---|
| container_issue | 4 |
| container_start_page | 667 |
| container_title | Obstetrics and gynecology (New York. 1953) |
| container_volume | 86 |
| creator | van Gelder-Hasker, M.R. de Jong, C.L.D. de Vries, J.I.P. van Geijn, H.P. |
| description | Fetal supraventricular tachycardia is most often treated by maternal application of digoxin. A drug used for second-choice therapy is flecainide acetate.
For a case in which maternal digoxin therapy failed, flecainide caused a lowering of the fetal heart rate (FHR) but, simultaneously, variability and accelerations nearly disappeared. The fetus demonstrated a normal movement pattern. Fetal well-being during delivery was assessed by regular ultrasound observations of fetal movements. Flecainide was not continued after birth, and digoxin therapy was started when tachycardia reappeared. The heart rate changed into a reactive pattern 5 days after birth. Around that time, flecainide levels in the neonatal serum were below the limit of detection.
Flecainide use can cause the absence of accelerations and poor variability in the FHR. |
| doi_str_mv | 10.1016/0029-7844(95)00028-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77523620</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>002978449500028P</els_id><sourcerecordid>77523620</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4314-dbd17b321dc5908210a032f55ed869d97ef1dc52e1c14fd14ee4e3cb424ffe643</originalsourceid><addsrcrecordid>eNp9kU1rVDEUhoModVr9BwpZiOjiaj5v7u1CKKV-QKFdVHAXcpMTJpq5d0wyLf33Js4wuHKTr_O-55w8B6FXlHyghPYfCWFjpwYh3o3yPam3obt9glZ0ULxjnP94ilZHyXN0mvPPKqL9yE_QieqVFESt0M3dGjB4D7bgxWMfwZowBwfYWCimAF5m7Osp4jWYVHBqb_cmBTOFGMrjOb7A1mTACbZLKi_QM29ihpeH_Qx9_3x1d_m1u7758u3y4rqzglPRuclRNXFGnZUjGRglhnDmpQQ39KMbFfgWYkAtFd5RASCA20kwUXvtBT9Db_d5t2n5vYNc9CZkCzGaGZZd1kpJxntGqlDshTYtOSfwepvCxqRHTYluHHWDpBskPUr9l6O-rbbXh_y7aQPuaDqAq_E3h7jJ1kSfzGxDPsp4rwiR_1R_WGKBlH_F3QMkXVHGsm7FSM8k6eg4Stqm07Wl_e7T3gYV4X2ojmwDzBZcSHVS2i3h_-3_AeL2nZI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77523620</pqid></control><display><type>article</type><title>The effect of flecainide acetate on fetal heart rate variability: A case report</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>van Gelder-Hasker, M.R. ; de Jong, C.L.D. ; de Vries, J.I.P. ; van Geijn, H.P.</creator><creatorcontrib>van Gelder-Hasker, M.R. ; de Jong, C.L.D. ; de Vries, J.I.P. ; van Geijn, H.P.</creatorcontrib><description>Fetal supraventricular tachycardia is most often treated by maternal application of digoxin. A drug used for second-choice therapy is flecainide acetate.
For a case in which maternal digoxin therapy failed, flecainide caused a lowering of the fetal heart rate (FHR) but, simultaneously, variability and accelerations nearly disappeared. The fetus demonstrated a normal movement pattern. Fetal well-being during delivery was assessed by regular ultrasound observations of fetal movements. Flecainide was not continued after birth, and digoxin therapy was started when tachycardia reappeared. The heart rate changed into a reactive pattern 5 days after birth. Around that time, flecainide levels in the neonatal serum were below the limit of detection.
Flecainide use can cause the absence of accelerations and poor variability in the FHR.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>DOI: 10.1016/0029-7844(95)00028-P</identifier><identifier>PMID: 7675407</identifier><identifier>CODEN: OBGNAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Antiarythmic agents ; Biological and medical sciences ; Cardiovascular system ; Female ; Fetal Diseases - drug therapy ; Flecainide - pharmacology ; Flecainide - therapeutic use ; Heart Rate, Fetal - drug effects ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Pregnancy ; Tachycardia, Supraventricular - drug therapy</subject><ispartof>Obstetrics and gynecology (New York. 1953), 1995-10, Vol.86 (4), p.667-669</ispartof><rights>1995 The American College of Obstetricians and Gynecologists</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4314-dbd17b321dc5908210a032f55ed869d97ef1dc52e1c14fd14ee4e3cb424ffe643</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3670050$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7675407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Gelder-Hasker, M.R.</creatorcontrib><creatorcontrib>de Jong, C.L.D.</creatorcontrib><creatorcontrib>de Vries, J.I.P.</creatorcontrib><creatorcontrib>van Geijn, H.P.</creatorcontrib><title>The effect of flecainide acetate on fetal heart rate variability: A case report</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>Fetal supraventricular tachycardia is most often treated by maternal application of digoxin. A drug used for second-choice therapy is flecainide acetate.
For a case in which maternal digoxin therapy failed, flecainide caused a lowering of the fetal heart rate (FHR) but, simultaneously, variability and accelerations nearly disappeared. The fetus demonstrated a normal movement pattern. Fetal well-being during delivery was assessed by regular ultrasound observations of fetal movements. Flecainide was not continued after birth, and digoxin therapy was started when tachycardia reappeared. The heart rate changed into a reactive pattern 5 days after birth. Around that time, flecainide levels in the neonatal serum were below the limit of detection.
Flecainide use can cause the absence of accelerations and poor variability in the FHR.</description><subject>Adult</subject><subject>Antiarythmic agents</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Female</subject><subject>Fetal Diseases - drug therapy</subject><subject>Flecainide - pharmacology</subject><subject>Flecainide - therapeutic use</subject><subject>Heart Rate, Fetal - drug effects</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Tachycardia, Supraventricular - drug therapy</subject><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1rVDEUhoModVr9BwpZiOjiaj5v7u1CKKV-QKFdVHAXcpMTJpq5d0wyLf33Js4wuHKTr_O-55w8B6FXlHyghPYfCWFjpwYh3o3yPam3obt9glZ0ULxjnP94ilZHyXN0mvPPKqL9yE_QieqVFESt0M3dGjB4D7bgxWMfwZowBwfYWCimAF5m7Osp4jWYVHBqb_cmBTOFGMrjOb7A1mTACbZLKi_QM29ihpeH_Qx9_3x1d_m1u7758u3y4rqzglPRuclRNXFGnZUjGRglhnDmpQQ39KMbFfgWYkAtFd5RASCA20kwUXvtBT9Db_d5t2n5vYNc9CZkCzGaGZZd1kpJxntGqlDshTYtOSfwepvCxqRHTYluHHWDpBskPUr9l6O-rbbXh_y7aQPuaDqAq_E3h7jJ1kSfzGxDPsp4rwiR_1R_WGKBlH_F3QMkXVHGsm7FSM8k6eg4Stqm07Wl_e7T3gYV4X2ojmwDzBZcSHVS2i3h_-3_AeL2nZI</recordid><startdate>199510</startdate><enddate>199510</enddate><creator>van Gelder-Hasker, M.R.</creator><creator>de Jong, C.L.D.</creator><creator>de Vries, J.I.P.</creator><creator>van Geijn, H.P.</creator><general>Elsevier Inc</general><general>The American College of Obstetricians and Gynecologists</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199510</creationdate><title>The effect of flecainide acetate on fetal heart rate variability: A case report</title><author>van Gelder-Hasker, M.R. ; de Jong, C.L.D. ; de Vries, J.I.P. ; van Geijn, H.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4314-dbd17b321dc5908210a032f55ed869d97ef1dc52e1c14fd14ee4e3cb424ffe643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Antiarythmic agents</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Female</topic><topic>Fetal Diseases - drug therapy</topic><topic>Flecainide - pharmacology</topic><topic>Flecainide - therapeutic use</topic><topic>Heart Rate, Fetal - drug effects</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Tachycardia, Supraventricular - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Gelder-Hasker, M.R.</creatorcontrib><creatorcontrib>de Jong, C.L.D.</creatorcontrib><creatorcontrib>de Vries, J.I.P.</creatorcontrib><creatorcontrib>van Geijn, H.P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Gelder-Hasker, M.R.</au><au>de Jong, C.L.D.</au><au>de Vries, J.I.P.</au><au>van Geijn, H.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of flecainide acetate on fetal heart rate variability: A case report</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>1995-10</date><risdate>1995</risdate><volume>86</volume><issue>4</issue><spage>667</spage><epage>669</epage><pages>667-669</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><coden>OBGNAS</coden><abstract>Fetal supraventricular tachycardia is most often treated by maternal application of digoxin. A drug used for second-choice therapy is flecainide acetate.
For a case in which maternal digoxin therapy failed, flecainide caused a lowering of the fetal heart rate (FHR) but, simultaneously, variability and accelerations nearly disappeared. The fetus demonstrated a normal movement pattern. Fetal well-being during delivery was assessed by regular ultrasound observations of fetal movements. Flecainide was not continued after birth, and digoxin therapy was started when tachycardia reappeared. The heart rate changed into a reactive pattern 5 days after birth. Around that time, flecainide levels in the neonatal serum were below the limit of detection.
Flecainide use can cause the absence of accelerations and poor variability in the FHR.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>7675407</pmid><doi>10.1016/0029-7844(95)00028-P</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0029-7844 |
| ispartof | Obstetrics and gynecology (New York. 1953), 1995-10, Vol.86 (4), p.667-669 |
| issn | 0029-7844 1873-233X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77523620 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Antiarythmic agents Biological and medical sciences Cardiovascular system Female Fetal Diseases - drug therapy Flecainide - pharmacology Flecainide - therapeutic use Heart Rate, Fetal - drug effects Humans Medical sciences Pharmacology. Drug treatments Pregnancy Tachycardia, Supraventricular - drug therapy |
| title | The effect of flecainide acetate on fetal heart rate variability: A case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A01%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20flecainide%20acetate%20on%20fetal%20heart%20rate%20variability:%20A%20case%20report&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=van%20Gelder-Hasker,%20M.R.&rft.date=1995-10&rft.volume=86&rft.issue=4&rft.spage=667&rft.epage=669&rft.pages=667-669&rft.issn=0029-7844&rft.eissn=1873-233X&rft.coden=OBGNAS&rft_id=info:doi/10.1016/0029-7844(95)00028-P&rft_dat=%3Cproquest_cross%3E77523620%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77523620&rft_id=info:pmid/7675407&rft_els_id=002978449500028P&rfr_iscdi=true |